Discovery of thieno[2,3- d ]pyrimidine-based dual Aurora B/VEGFR-2 inhibitors with potent anticancer activity: molecular docking, mechanistic studies, and in vivo validation in a breast cancer model

Hamed W. El-Shafey; Abdelrahman Hamdi; Mohamed R. Elnagar; Sahar M. Gebril; Abdullah Haikal; Adel S. El‐Azab; Simone Brogi; Ibrahim A. Al-Suwaidan; Alaa A.‐M. Abdel‐Aziz

doi:10.1039/d5ra09370h

January 1, 2026RSC AdvancesOpen Access

Discovery of thieno[2,3- d ]pyrimidine-based dual Aurora B/VEGFR-2 inhibitors with potent anticancer activity: molecular docking, mechanistic studies, and in vivo validation in a breast cancer model

View Full Paper

Ask AI

Bookmark

Share

Key Points

The aim is to discover new dual inhibitors targeting Aurora B and VEGFR-2 with enhanced anticancer properties.
Molecular docking to analyze interactions between compounds and targets.
In vitro and in vivo studies to evaluate the efficacy of the inhibitors in breast cancer models.
The dual inhibitors showed significant anticancer activity in vitro and in vivo.
Enhanced inhibition of cancer cell proliferation and tumor growth compared to existing treatments.

Implication

Experiments demonstrate anticancer activity of new dual inhibitors in breast cancer, suggesting potential for improved therapies.

Abstract

Breast cancer continues to be the most common malignancy in women and a major contributor of cancer-related mortality, emphasizing the need for novel therapeutic agents.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

El-Shafey et al. (2026) studied this question.

synapsesocial.com/papers/69eb0b8d553a5433e34b528c https://doi.org/10.1039/d5ra09370h

View Full Paper

Ask AI

Bookmark

Share

Discovery of thieno[2,3- d ]pyrimidine-based dual Aurora B/VEGFR-2 inhibitors with potent anticancer activity: molecular docking, mechanistic studies, and in vivo validation in a breast cancer model

Key Points

Implication

Abstract

Discussion

Cite This Study

Discovery of thieno[2,3- d ]pyrimidine-based dual Aurora B/VEGFR-2 inhibitors with potent anticancer activity: molecular docking, mechanistic studies, and in vivo validation in a breast cancer model

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading